1
|
Kelam LM, Chhabra V, Dhiman S, Kumari D, Sobhia ME. Protein tyrosine phosphatase inhibitors: a patent review and update (2012-2023). Expert Opin Ther Pat 2024; 34:187-209. [PMID: 38920057 DOI: 10.1080/13543776.2024.2362203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Accepted: 05/28/2024] [Indexed: 06/27/2024]
Abstract
INTRODUCTION Protein tyrosine phosphatases (PTPs), essential and evolutionarily highly conserved enzymes, govern cellular functions by modulating tyrosine phosphorylation, a pivotal post-translational modification for signal transduction. The recent strides in phosphatase drug discovery, leading to the identification of selective modulators for enzymes, restoring interest in the therapeutic targeting of protein phosphatases. AREAS COVERED The compilation of patents up to the year 2023 focuses on the efficacy of various classes of Tyrosine phosphatases and their inhibitors, detailing their chemical structure and biochemical characteristics. These findings have broad implications, as they can be applied to treating diverse conditions like cancer, diabetes, autoimmune disorders, and neurological diseases. The search for scientific articles and patent literature was conducted using well known different platforms to gather information up to 2023. EXPERT OPINION The latest improvements in protein tyrosine phosphatase (PTP) research include the discovery of new inhibitors targeting specific PTP enzymes, with a focus on developing allosteric site covalent inhibitors for enhanced efficacy and specificity. These advancements have not only opened up new possibilities for therapeutic interventions in various disease conditions but also hold the potential for innovative treatments. PTPs offer promising avenues for drug discovery efforts and innovative treatments across a spectrum of health conditions.
Collapse
Affiliation(s)
- Lakshmi Mounika Kelam
- Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India
| | - Vaishnavi Chhabra
- Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India
| | - Sarika Dhiman
- Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India
| | - Deevena Kumari
- Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India
| | | |
Collapse
|
2
|
Computational Methods in Cooperation with Experimental Approaches to Design Protein Tyrosine Phosphatase 1B Inhibitors in Type 2 Diabetes Drug Design: A Review of the Achievements of This Century. Pharmaceuticals (Basel) 2022; 15:ph15070866. [PMID: 35890163 PMCID: PMC9322956 DOI: 10.3390/ph15070866] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2022] [Revised: 07/10/2022] [Accepted: 07/12/2022] [Indexed: 02/04/2023] Open
Abstract
Protein tyrosine phosphatase 1B (PTP1B) dephosphorylates phosphotyrosine residues and is an important regulator of several signaling pathways, such as insulin, leptin, and the ErbB signaling network, among others. Therefore, this enzyme is considered an attractive target to design new drugs against type 2 diabetes, obesity, and cancer. To date, a wide variety of PTP1B inhibitors that have been developed by experimental and computational approaches. In this review, we summarize the achievements with respect to PTP1B inhibitors discovered by applying computer-assisted drug design methodologies (virtual screening, molecular docking, pharmacophore modeling, and quantitative structure–activity relationships (QSAR)) as the principal strategy, in cooperation with experimental approaches, covering articles published from the beginning of the century until the time this review was submitted, with a focus on studies conducted with the aim of discovering new drugs against type 2 diabetes. This review encourages the use of computational techniques and includes helpful information that increases the knowledge generated to date about PTP1B inhibition, with a positive impact on the route toward obtaining a new drug against type 2 diabetes with PTP1B as a molecular target.
Collapse
|
3
|
Recent Updates on Development of Protein-Tyrosine Phosphatase 1B Inhibitors for Treatment of Diabetes, Obesity and Related Disorders. Bioorg Chem 2022; 121:105626. [DOI: 10.1016/j.bioorg.2022.105626] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 12/19/2021] [Accepted: 01/13/2022] [Indexed: 01/30/2023]
|
4
|
Gevondian AG, Kotovshchikov YN, Latyshev GV, Lukashev NV, Beletskaya IP. Domino Construction of Benzoxazole-Derived Sulfonamides via Metal-Free Denitrogenation of 5-Iodo-1,2,3-triazoles in the Presence of SO 2 and Amines. J Org Chem 2021; 86:5639-5650. [PMID: 33822625 DOI: 10.1021/acs.joc.1c00115] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A straightforward domino approach to assemble benzoxazole-derived sulfonamides has been developed. The method is based on annulation-induced in situ generation of diazo compounds from readily available 2-(5-iodo-1,2,3-triazolyl)phenols, followed by metal-free denitrogenative transformation upon the action of 1,4-diazabicyclo[2.2.2]octane bis(sulfur dioxide) (DABSO) and amines. The protocol is operationally simple and features a broad substrate scope, furnishing a library of target compounds in generally good yields.
Collapse
Affiliation(s)
- Avetik G Gevondian
- Chemistry Department, M. V. Lomonosov Moscow State University, Leninskiye Gory 1/3, Moscow 119991, Russia
| | - Yury N Kotovshchikov
- Chemistry Department, M. V. Lomonosov Moscow State University, Leninskiye Gory 1/3, Moscow 119991, Russia
| | - Gennadij V Latyshev
- Chemistry Department, M. V. Lomonosov Moscow State University, Leninskiye Gory 1/3, Moscow 119991, Russia
| | - Nikolay V Lukashev
- Chemistry Department, M. V. Lomonosov Moscow State University, Leninskiye Gory 1/3, Moscow 119991, Russia
| | - Irina P Beletskaya
- Chemistry Department, M. V. Lomonosov Moscow State University, Leninskiye Gory 1/3, Moscow 119991, Russia
| |
Collapse
|
5
|
West MJ, Fyfe JWB, Vantourout JC, Watson AJB. Mechanistic Development and Recent Applications of the Chan–Lam Amination. Chem Rev 2019; 119:12491-12523. [DOI: 10.1021/acs.chemrev.9b00491] [Citation(s) in RCA: 159] [Impact Index Per Article: 31.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Matthew J. West
- EaStCHEM, School of Chemistry, University of St Andrews, North Haugh, St Andrews, Fife KY16 9ST, U.K
| | - James W. B. Fyfe
- EaStCHEM, School of Chemistry, University of St Andrews, North Haugh, St Andrews, Fife KY16 9ST, U.K
| | - Julien C. Vantourout
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Allan J. B. Watson
- EaStCHEM, School of Chemistry, University of St Andrews, North Haugh, St Andrews, Fife KY16 9ST, U.K
| |
Collapse
|
6
|
The development of protein tyrosine phosphatase1B inhibitors defined by binding sites in crystalline complexes. Future Med Chem 2019; 10:2345-2367. [PMID: 30273014 DOI: 10.4155/fmc-2018-0089] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Protein tyrosine phosphatase1B (PTP1B), a significant negative regulator in insulin and leptin signaling pathways, has emerged as a promising drug target for Type II diabetes mellitus and obesity. Numerous potent PTP1B inhibitors have been discovered within both academia and pharmaceutical industry. However, nearly all medicinal chemistry efforts have been severely hindered because a vast majority of them demonstrate poor membrane permeability and low-selectivity, especially over T-cell protein tyrosine phosphatase (TCPTP). To search the rules about the selectivity over TCPTP and membrane permeability of PTP1B inhibitors, based on the PTP1B/inhibitor crystal complexes, the development PTP1B inhibitors defined as AB, AC, ABC and ADC types have been concluded in the review.
Collapse
|
7
|
Abstract
The development of benzoxazole containing drugs and research compounds has been discussed in the present review along with its varied pharmacological activities such as antimicrobial, antiinflammatory, anticancer, antiviral, antiasthmatic, antitubercular, anticonvulsant, lipid modulating, anticoagulants, antidiabetic and anthelmintic activities. The present review is a compilation of the biological activities determined in the research work conducted on benzoxazole-based compounds fused and linked with various other heterocycles.
Collapse
Affiliation(s)
- Mayura Kale
- Government College of Pharmacy, Osmanpura, Aurangabad-431005, Maharashtra, India
| | | |
Collapse
|
8
|
Łukowska-Chojnacka E, Kowalkowska A, Napiórkowska A. Lipase-catalyzed kinetic resolution of novel antitubercular benzoxazole derivatives. Chirality 2017; 30:457-468. [DOI: 10.1002/chir.22806] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Revised: 10/11/2017] [Accepted: 11/22/2017] [Indexed: 01/31/2023]
Affiliation(s)
| | - Anna Kowalkowska
- Faculty of Chemistry; Warsaw University of Technology; Warsaw Poland
| | - Agnieszka Napiórkowska
- Microbiology Department; National Tuberculosis and Lung Diseases Research Institute; Warsaw Poland
| |
Collapse
|
9
|
Wang H, Gu D, Wang M, Guo H, Wu H, Tian G, Li Q, Yang Y, Tian J. A strategy based on gas chromatography–mass spectrometry and virtual molecular docking for analysis and prediction of bioactive composition in natural product essential oil. J Chromatogr A 2017; 1501:128-133. [DOI: 10.1016/j.chroma.2017.04.031] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Revised: 04/12/2017] [Accepted: 04/13/2017] [Indexed: 11/24/2022]
|
10
|
Li XQ, Xu Q, Luo J, Wang LJ, Jiang B, Zhang RS, Shi DY. Design, synthesis and biological evaluation of uncharged catechol derivatives as selective inhibitors of PTP1B. Eur J Med Chem 2017; 136:348-359. [PMID: 28511130 DOI: 10.1016/j.ejmech.2017.05.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2017] [Revised: 04/27/2017] [Accepted: 05/02/2017] [Indexed: 11/27/2022]
Abstract
Protein tyrosine phosphatases 1B (PTP1B) is a promising and validated therapeutic target to effectively treat T2DM and obesity. However, the development of charged PTP1B inhibitors was restricted due to their low cell permeability and poor bioavailability. Based on active natural products, two series of uncharged catechol derivatives were identified as PTP1B inhibitors by targeting a secondary aryl phosphate-binding site as well as the catalytic site. The most potent inhibitor 22 showed an IC50 of 0.487 μM against PTP1B and strong selectivity (27-fold) over TCPTP. Kinetic studies were also performed that 22 act as a competitive PTP1B inhibitor. The treatment of C2C12 myotubes with 22 markedly increased the phosphorylation levels of IRβ, Akt and IRS1 phosphorylation. The similarity of its action profiling with that produced by insulin suggested its potential as a new non-insulin-dependent drug candidate.
Collapse
Affiliation(s)
- Xiang-Qian Li
- Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, China; Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao, China
| | - Qi Xu
- Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, China; Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao, China; University of Chinese Academy of Sciences, Beijing, China
| | - Jiao Luo
- Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, China; Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao, China; University of Chinese Academy of Sciences, Beijing, China
| | - Li-Jun Wang
- Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, China; Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao, China
| | - Bo Jiang
- Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, China; Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao, China
| | - Ren-Shuai Zhang
- Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, China; Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao, China
| | - Da-Yong Shi
- Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, China; Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao, China; University of Chinese Academy of Sciences, Beijing, China.
| |
Collapse
|
11
|
|
12
|
Recent advances in the development of protein tyrosine phosphatase 1B inhibitors for Type 2 diabetes. Future Med Chem 2016; 8:1239-58. [PMID: 27357615 DOI: 10.4155/fmc-2016-0064] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Diabetes mellitus is the most serious and prevalent metabolic disorders worldwide, complications of which can decrease significantly the quality of life and contribute to premature death. Resistance to insulin is a predominant pathophysiological factor of Type 2 diabetes (T2D). Protein tyrosine phosphatase 1B (PTP1B) is an important negative factor of insulin signal and a potent therapeutic target in T2D patients. This review highlights recent advances (2012-2015) in research related to the role of PTP1B in signal transduction processes implicated in pathophysiology of T2D, and novel PTP1B inhibitors with an emphasis on their chemical structures and modes of action.
Collapse
|
13
|
Schmidt B, Wolf F, Brunner H. Styrylsulfonates and -Sulfonamides through Pd-Catalysed Matsuda-Heck Reactions of Vinylsulfonic Acid Derivatives and Arenediazonium Salts. European J Org Chem 2016. [DOI: 10.1002/ejoc.201600469] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Bernd Schmidt
- Institut für Chemie; Universität Potsdam; Karl-Liebknecht-Strasse 24-25 14476 Potsdam-Golm Germany
| | - Felix Wolf
- Institut für Chemie; Universität Potsdam; Karl-Liebknecht-Strasse 24-25 14476 Potsdam-Golm Germany
| | - Heiko Brunner
- Atotech Deutschland GmbH; Erasmusstrasse 20 10553 Berlin Germany
| |
Collapse
|
14
|
Váradi A, Palmer TC, Notis Dardashti R, Majumdar S. Isocyanide-Based Multicomponent Reactions for the Synthesis of Heterocycles. Molecules 2015; 21:E19. [PMID: 26703561 PMCID: PMC4782750 DOI: 10.3390/molecules21010019] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2015] [Revised: 12/02/2015] [Accepted: 12/17/2015] [Indexed: 11/16/2022] Open
Abstract
Multicomponent reactions (MCRs) are extremely popular owing to their facile execution, high atom-efficiency and the high diversity of products. MCRs can be used to access various heterocycles and highly functionalized scaffolds, and thus have been invaluable tools in total synthesis, drug discovery and bioconjugation. Traditional isocyanide-based MCRs utilize an external nucleophile attacking the reactive nitrilium ion, the key intermediate formed in the reaction of the imine and the isocyanide. However, when reactants with multiple nucleophilic groups (bisfunctional reactants) are used in the MCR, the nitrilium intermediate can be trapped by an intramolecular nucleophilic attack to form various heterocycles. The implications of nitrilium trapping along with widely applied conventional isocyanide-based MCRs in drug design are discussed in this review.
Collapse
Affiliation(s)
- András Váradi
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
| | - Travis C Palmer
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
| | | | - Susruta Majumdar
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
| |
Collapse
|
15
|
Singh S, Veeraswamy G, Bhattarai D, Goo JI, Lee K, Choi Y. Recent Advances in the Development of Pharmacologically Active Compounds that Contain a Benzoxazole Scaffold. ASIAN J ORG CHEM 2015. [DOI: 10.1002/ajoc.201500235] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Sarbjit Singh
- College of Pharmacy; Dongguk University-Seoul; Republic of Korea
| | - Gajulapati Veeraswamy
- College of Life Science and Biotechnology; Korea University-Seoul; Republic of Korea
| | - Deepak Bhattarai
- College of Pharmacy; Dongguk University-Seoul; Republic of Korea
| | - Ja-Il Goo
- College of Life Science and Biotechnology; Korea University-Seoul; Republic of Korea
| | - Kyeong Lee
- College of Pharmacy; Dongguk University-Seoul; Republic of Korea
| | - Yongseok Choi
- College of Life Science and Biotechnology; Korea University-Seoul; Republic of Korea
| |
Collapse
|
16
|
Demmer CS, Bunch L. Benzoxazoles and oxazolopyridines in medicinal chemistry studies. Eur J Med Chem 2014; 97:778-85. [PMID: 25487760 DOI: 10.1016/j.ejmech.2014.11.064] [Citation(s) in RCA: 90] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Revised: 11/14/2014] [Accepted: 11/30/2014] [Indexed: 12/20/2022]
Abstract
The benzoxazole heterocycle is often found in ligands targeting a plethora of receptors and enzymes. By analysis of published X-ray structures, this review aims at highlighting key interactions which the benzoxazole may engage in with its host protein. Furthermore, bioavailability, metabolism and the use of benzoxazole as a bioisostere are discussed. The review is extended to cover structure-activity relationship studies of 2-substituted benzoxazoles, 2-substituted oxazolopyridines, and in perspective, application of the recently published novel heterocycle oxazolopyrazine in medicinal chemistry studies.
Collapse
Affiliation(s)
- Charles S Demmer
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark
| | - Lennart Bunch
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.
| |
Collapse
|
17
|
Synthesis and biological evaluation of novel thiadiazole amides as potent Cdc25B and PTP1B inhibitors. Bioorg Med Chem Lett 2014; 24:4125-8. [DOI: 10.1016/j.bmcl.2014.07.055] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Revised: 07/05/2014] [Accepted: 07/19/2014] [Indexed: 01/31/2023]
|
18
|
Váradi A, Palmer TC, Notis PR, Redel-Traub GN, Afonin D, Subrath JJ, Pasternak GW, Hu C, Sharma I, Majumdar S. Three-component coupling approach for the synthesis of diverse heterocycles utilizing reactive nitrilium trapping. Org Lett 2014; 16:1668-71. [PMID: 24580074 PMCID: PMC3969103 DOI: 10.1021/ol500328t] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
![]()
The
formation of an unexpected heterocyclic scaffold, a benzoxazole,
in a three-component reaction between a ketone, isocyanide, and 2-aminophenol
was encountered. This reaction involved a benzo[b][1,4]oxazine intermediate resulting from intramolecular attack of
the aminophenol hydroxyl group on the nitrilium ion. Unlike previous
literature examples, the trapped nitrilium benzo[b][1,4]oxazine could readily be subjected to ring opening with bis-nucleophiles.
The reaction scope includes simple linear as well as complex cyclic
ketones and substituted 2-aminophenols. A representative benzoxazole
product could be further diversified to yield drug-like compounds.
Collapse
Affiliation(s)
- András Váradi
- Department of Neurology, Memorial Sloan Kettering Cancer Center , 1275 York Avenue, New York, New York 10065, United States
| | | | | | | | | | | | | | | | | | | |
Collapse
|